Engineering PEG10 assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination (Updated July 17, 2024).

A preprint abstract discusses the potential of tumor neoantigen peptide vaccines for cancer immunotherapy. The abstract highlights the challenges of efficiently delivering peptides and adjuvants to antigen-presenting cells in vivo. The researchers propose a novel protein carrier called ePAC, which is designed to self-assemble into endogenous virus-like particles (eVLP) and deliver genetically encoded neoantigens to dendritic cells. The study shows promising results in mouse and humanized mouse tumor models, suggesting that ePAC could be used as a safe and effective cancer vaccine for antitumor therapy. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]